Over 2,200+ pages in 22 languages!
 
LUNG (PULMONARY): MAIN MENU
Lung (Pulmonary) Overview
Aspiration Pneumonia
Oxygen Therapy
Pleural Effusion
Pulmonary Fibrosis
Pulmonary Hypertension
Preventive Care
Pulmonary Support Resources
Pulmonary Hypertension
What is PH?
Primary PH
Isolated PH
Secondary PH
Exercised Induced PH
PH Disease Correlations
Symptoms
Diagnosis
Prognosis
Treatments
Research Registries
Research
Patient Support Organizations
Personal Stories
Treatments for Pulmonary Hypertension
Bosentan/Tracleer
Endothelin Receptors (Sitaxsentan/Ambrisentan)
Inhaled Prostacyclin (Ventavis, Iloprost)
Heart/Lung Transplants
Prostacyclin (Flolan, Epoprostenol) Warning
Sildenafil Citrate (Revatio, Viagra)
Stem Cell Transplant
Warfarin (Coumadin)
Treatments for Pulmonary Hypertension: Lung Transplants
Many centers do not approve heart or lung transplants for Scleroderma patients, however, a few of them do, so contact the Second Wind Lung Transplant Association for further information.
First Mouse Lung Transplants Lay Groundwork For New Ways To Prevent Transplant Rejection In Humans. Surgeons have developed the first mouse model of lung transplantation, and they're hoping it will help explain why the success of the procedure in humans lags far behind other solid organ transplants. Five years after lung transplant surgery, only about 45 percent of patients are still alive. ScienceDaily. Washington University School of Medicine. 07/13/07.
Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis (IPF) and idiopathic pulmonary arterial hypertension (IPAH). Patients with scleroderma who are recipients of lung transplantation experience similar rates of survival 2 years after the procedure compared with those with IPF or IPAH. Lung transplantation may represent a viable therapeutic option to consider for patients with end-stage lung disease due to scleroderma. PubMed. Arthritis Rheum. 2006 Dec;54(12):3954-61. (Also see: Pulmonary Fibrosis)
Essential pulmonary arterial hypertension. The recent discovery of BMPR2, a dominant gene with weak penetrance, has opened up several interesting possibilities in this setting. Pathophysiological research has identified a fall in vasodilatory substances and an increase in vasoconstrictive mediators, opening the way to medical treatments that can postpone the need for lung transplantation. PubMed. Bull Acad Natl Med. 2005 Mar;189(3):523-33; discussion 533-4.
Keep on Surfing!
Go to Inhaled Prostacyclin
Contact ISN. We are a full-service nonprofit agency.
Email: isn@sclero.org or
Post in Sclero Forums!
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702
USA
Toll Free Hotline in U.S.
1-800-564-7099
Direct Line
1-952-831-3091 (U.S.)
(We are also known as the Scleroderma from A to Z web site.)
© Copyright 1998-2008 International Scleroderma Network
All Rights Reserved